ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)

K. Pedersen; N. Foster; M. Overman; P. Boland; S. Kim; K. Arrambide; B. Jaszewski; J. Welch; R. Wilson; R. McWilliams

doi:10.1093/annonc/mdz154.006

ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)

K. Pedersen, N. Foster, M. Overman, P. Boland, S. Kim, K. Arrambide, B. Jaszewski, J. Welch, R. Wilson, R. McWilliams

Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	iv128
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz154.006
State	Published - Jul 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz154.006

Cite this

Pedersen, K., Foster, N., Overman, M., Boland, P., Kim, S., Arrambide, K., Jaszewski, B., Welch, J., Wilson, R., & McWilliams, R. (2019). ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA). Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv128. https://doi.org/10.1093/annonc/mdz154.006

Pedersen, K, Foster, N, Overman, M, Boland, P, Kim, S, Arrambide, K, Jaszewski, B, Welch, J, Wilson, R & McWilliams, R 2019, 'ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. iv128. https://doi.org/10.1093/annonc/mdz154.006

@article{7c1a32685a5d44b5a25dbde04c23e18c,

title = "ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)",

author = "K. Pedersen and N. Foster and M. Overman and P. Boland and S. Kim and K. Arrambide and B. Jaszewski and J. Welch and R. Wilson and R. McWilliams",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz154.006",

language = "English (US)",

volume = "30",

pages = "iv128",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - ZEBRA

T2 - an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)

AU - Pedersen, K.

AU - Foster, N.

AU - Overman, M.

AU - Boland, P.

AU - Kim, S.

AU - Arrambide, K.

AU - Jaszewski, B.

AU - Welch, J.

AU - Wilson, R.

AU - McWilliams, R.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85072636187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072636187&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz154.006

DO - 10.1093/annonc/mdz154.006

M3 - Article

C2 - 32085020

SN - 0923-7534

VL - 30

SP - iv128

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this